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Introduction
The idiopathic inflammatory myopathies (IIM) 
are a rare and heterogeneous group of acquired 
autoimmune muscle disorders, often referred to 
as ‘myositis’. This review will focus on selected 
aspects of the current management of adult-onset 
IIM, but largely omit sporadic inclusion body 
myositis (IBM), for which no effective disease-
modifying treatments currently exist.
For many years, IIM has been classified simply as 
either polymyositis (PM) or dermatomyositis 
(DM). However, the definition of IIM subtypes is 
currently undergoing upheaval as a consequence 
of our increased understanding of the genetic and 
serological associations with certain clinical phe-
notypes. Emphasis is now on defining clinicosero-
logical syndromes that can inform treatment 
response, predict the likelihood of developing cer-
tain clinical features and thus guide therapeutic 
decision making [Betteridge and McHugh, 2015].
Underlying pathological mechanisms remain 
poorly understood in IIM and the mainstay 
of treatment continues to be the unfocused 
‘immunosuppression’. Little progress has been 
made towards a more stratified (precision medi-
cine) approach targeting specific pathological 
processes, as is occurring in other autoimmune 
disorders such as rheumatoid arthritis [Okada 
et al. 2014]. Additionally, fully standardized and 
validated methods for monitoring disease activity 
and treatment response remain elusive [Miller, 
2012]. As a consequence, outcomes in IIM treat-
ment continue to be generally poor. Patients can 
suffer refractory muscle weakness and fatigue, in 
addition to extramuscular manifestations (e.g. 
skin disease, cardiac and respiratory involvement, 
etc.) that can be difficult to control. Furthermore, 
mortality rates are increased compared with nor-
mal individuals, and the association of adult DM 
with malignancy remains a significant additional 
concern [Dobloug et al. 2015].
Another issue is that patients can sometimes ‘fall 
between stools’ and the differing approach of 
neurologists and rheumatologists has been noted 
[Christopher-Stine, 2010]. In fact, IIM patients 
will often need input from respiratory physicians, 
dermatologists, rehabilitation specialists, pain 
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specialists and other allied health professionals 
(e.g. pharmacist, physiotherapist, occupational 
therapist, and speech and language therapist) in 
additional to their parent physician. Treating 
patients with IIM is complex, and thus requires 
close cooperation between these care providers.
Classification
IIM is heterogeneous, and accurate subtype clas-
sification is fundamental if one is to treat the dis-
ease effectively. Accurate diagnosis relies upon a 
combination of clinical characteristics, muscle 
biopsy histopathology findings and serology. 
Traditionally, reliance was made upon the Bohan 
and Peter diagnostic criteria [Bohan and Peter, 
1975a, 1975b], which does show good discrimi-
natory ability when distinguishing between PM/
DM and systemic lupus erythematosus or sys-
temic sclerosis (sensitivity 93%, and specificity 
93%) [Oddis and Medsger, 1995].
However, these criteria have a number of limita-
tions. In particular, no reference is made to IBM, 
which was still being referred to as ‘steroid-resistant 
PM’ at the time the criteria were envisioned. 
Reliance on the Bohan and Peter criteria means 
that patients with IBM, and other PM mimics 
such as muscular dystrophy, risk being misdiag-
nosed as having PM. Furthermore, these criteria 
do not make reference to serological or muscle-
imaging findings, both of which are increasingly 
used in the diagnostic work-up of IIM patients. In 
summary, it is now clear that the Bohan and Peter 
criteria are outdated and should not be relied 
upon. The more recent criteria developed by 
Hoogendijk and colleagues added important exclu-
sion criteria, to avoid misdiagnosis of IBM as PM 
and to reduce the likelihood of noninflammatory 
muscle disease being misclassified as IIM 
[Hoogendijk et al. 2004]. Serology (the presence of 
myositis-specific antibodies) and myo-oedma on 
magnetic resonance imaging (MRI) were also 
added, although only to support a ‘probable’ rather 
than ‘definite’ diagnosis of either PM or DM.
Further criteria are being developed using a multi-
centre data-driven approach and are currently 
undergoing an ACR/EULAR approval process. 
The criteria (for which an online calculator is avail-
able at: http://www.imm.ki.se/biostatistics/calcula-
tors/iim/) were produced after analysis of pooled 
demographic, clinical and laboratory data on 976 
IIM patients and 624 controls. The calculator can 
be used with or without the availability of muscle 
biopsy data and produces a probability that the 
patient has IIM as well as a suggested subgroup 
(e.g. DM, PM or IBM). A predetermined mini-
mum probability of 50% is suggested to define IIM 
cases, but a more stringent threshold of 90% is 
suggested for inclusion in clinical trials.
Importantly, pure PM now appears to be a dis-
tinctly rare entity [Dalakas, 2015]. It is more com-
mon, for instance, for muscle inflammation to 
occur as a feature of the antisynthetase syndrome 
(which also includes features such as fever, arthral-
gias, Raynaud’s phenomenon and ‘mechanics 
hands’), for which separate diagnostic criteria have 
been proposed [Connors et  al. 2010]. ‘PM’ may 
also form part of an overlap syndrome with other 
connective tissue diseases (CTD), such as mixed 
CTD or systemic sclerosis. Thus, features of these 
CTDs should be sought to aid classification 
and guide management. Necrotizing autoimmune 
myositis (NAM, also referred to as immune-
mediated necrotizing myopathy (IMNM)) has 
also become recognized as a distinct entity, which 
in the past may have been classified as PM. In 
NAM, antibodies against signal recognition parti-
cle (SRP) and 3 hydroxy-3 methylglutaryl- coen-
zyme A reductase (HMGCR) are usually identified 
and the muscle biopsy is characterized by the 
presence of myonecrosis with a relative paucity of 
inflammatory features [Hamann et al. 2013].
It is becoming clear that each clinical phenotype 
within the IIM spectrum is associated with a dis-
tinctive genetic and serological signature [Miller 
et al. 2015; Rothwell et al. 2015]. These develop-
ments are being gradually translated in to clinical 
practice. For example, the presence of anti- 
TIF1-gamma antibodies, which in adult DM 
patients strongly associates with the presence of 
malignancy, necessitates vigilant cancer screening 
[Trallero-Araguás et  al. 2012]. Other antibody 
profiles can be used to predict treatment 
responses. For example, DM patients with anti-
Mi-2 antibodies tend to respond well to immuno-
suppression [Aggarwal et al. 2014]. Further tools 
that allow a more accurate stratification of the 
heterogeneity of IIM are desirable in order to 
focus management efforts and exploit new thera-
peutic targets.
Clinical trials and the therapeutic evidence 
base
Recent efforts have led to the production of the 
semivalidated International Myositis Assessment 
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and Clinical Studies Group’s (IMACS) ‘core-set’ 
outcome measures [Rider et al. 2011] and ‘defini-
tion of improvement’ [Rider et al. 2003]. These 
are increasingly utilized in clinical trials as pri-
mary outcome measures. Also, there is now an 
international consensus statement regarding the 
conduct of clinical trials in IIM [Oddis et  al. 
2005].
The major strength of using the IMACS outcome 
measures is the multifaceted nature of the assess-
ment, which takes account of laboratory meas-
ures of muscle-enzyme levels [usually creatine 
kinase (CK)], manual muscle testing (MMT), as 
well as patient- [Health Assessment Questionnaire 
(HAQ) and global visual analogue scale] and phy-
sician-completed [Myositis Disease Activity 
Assessment Tool (MDAAT) and global visual 
analogue scale] scoring tools.
Difficulties in using these measures in clinical tri-
als do, however, remain. Not all measures are 
completely validated and some aspects exhibit a 
‘ceiling effect’, especially in patients with rela-
tively mild disease at the outset [Rider et al. 2011]. 
Furthermore, differentiating between disease 
damage (i.e. irreversible change to muscle such as 
fatty replacement with or without fibrosis) and 
disease activity (which is amenable to treatment) 
remains difficult. This distinction is of key rele-
vance when defining inclusion and exclusion cri-
teria for clinical trials in IIM [Miller, 2012].
Any discussion of the treatment of IIM must 
highlight that the evidence base is remarkably 
limited. Clinical trials for IIM have most often 
been small and underpowered, and until recently 
have not utilized standardized outcome meas-
ures. Another issue is that inclusion criteria have 
often been based on outdated definitions of IIM, 
and which did not take into account recent devel-
opments regarding serological associations with 
certain IIM phenotypes.
These strictures have resulted in an uninforma-
tive knowledge base and a lack of clear evidence-
based treatment algorithms. In the UK, there are, 
for instance, no licensed treatments for IIM, 
which are instead ‘borrowed’ from other diseases 
such as the CTDs. This issue was highlighted in a 
recent Cochrane review [Gordon et  al. 2012]. 
Treatment decisions in IIM are thus usually 
based on local expert options, or consensus of 
opinions, rather than on the results of randomized 
controlled trials.
In other disease where the evidence base is lack-
ing, consensus statements and ‘standards of care’ 
have been produced to guide practice. However, 
in the UK, no such statements exist. This is grad-
ually being addressed and there is ongoing work to 
produce a patient-derived standard of care state-
ment for IIM [Lilleker et al. 2015] as well as con-
sensus statements on treatment of IIM according 
to the phenotype observed [Tansley et al. 2014].
Magnetic resonance imaging of muscle
MRI is used increasingly in IIM for diagnostic 
purposes, to optimize diagnostic biopsy-site 
choice and to assess disease activity and damage 
during treatment. From a diagnostic perspective, 
MRI has identified differences between PM, DM 
and IBM, as well as between inflammatory dis-
ease of muscle versus noninflammatory mimics 
[Sekul et  al. 1997; Tomasová Studynková et  al. 
2007]. Performing targeted muscle biopsies based 
on the identification of areas of muscle inflamma-
tion on MRI has the potential to increase diag-
nostic yield [Tomasová Studynková et al. 2007].
Muscle MRI can indicate the degree of fatty 
replacement of muscle (e.g. using T1-weighted 
sequences) as well as estimate the intensity and 
extent of disease activity. The latter is inferred 
from the presence and extent of myo-oedema, as 
detected on short tau inversion recovery (STIR) 
sequences [Miller, 2012; Tomasová Studynková 
et al. 2007]. The distinction between irreversible 
disease damage and disease activity is critical 
when considering the likelihood of success of any 
therapeutic intervention.
Quantitative assessment of MRI findings is the 
focus of much research effort, with potential ben-
efits over the rather subjective approach currently 
taken which involves the use of semiquantitative 
scoring systems [Mercuri et al. 2007]. These sem-
iquantitative scoring tools currently lack valida-
tion, and different scales may be utilized in 
different centres. In contrast, quantitative MRI 
analysis [Yao et al. 2015] has the potential to pro-
vide a robust objective outcome measure for use 
in clinical trials, and also has the potential to feed 
automated image-analysis techniques that could 
be deployed in future clinical practice.
Treatment
Treatment of IIM will often focus on skeletal 
muscle disease. However, IIM is a multisystem 
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disorder and concern should be given to extra-
muscular aspects of the disease, particularly the 
skin in DM and the potential for respiratory and 
cardiac involvement. Also of relevance is the 
occurrence of other complicating issues, including 
pain, fatigue, dysphagia and depression, which 
should be addressed for each patient.
Whilst the IMACS outcome measures can also be 
used in clinical practice, a more holistic approach 
is often utilized which exploits the clinical exper-
tise of the treating physician as well as a number 
of other investigational modalities for assessing 
disease activity and damage, including MRI of 
muscle. A common mistake is to make treatment 
decisions based on change in an individual meas-
ure. For example, serum CK can fall without 
improvement in muscle strength, and levels can 
be normal even in those with obviously active dis-
ease [Dalakas and Hohlfeld, 2003]. The overall 
message is to ‘treat the patient, not the numbers’ 
and despite advances in technology, clinical 
examination remains vital if one is to successfully 
assess and treat IIM patients.
One aspect that needs highlighting is the issue of 
‘steroid resistance’. Very few accurately diag-
nosed PM or DM patients will resist response to 
corticosteroid therapy. Thus, when an individual 
case proves truly unresponsive to corticosteroids, 
the IIM diagnosis should be reviewed. This is 
particularly so in cases that are seronegative for all 
IIM-specific or -associated autoantibodies (MSA/
MAA). In this situation, there is a significant pos-
sibility that either the patient has IBM or another 
IIM mimic, such as a muscular dystrophy. 
Importantly, a number of dystrophic conditions 
(e.g. limb girdle muscular dystrophy 2B, a dysfer-
linopathy) are associated with an inflammatory 
appearance on muscle biopsy, which can lead to 
diagnostic confusion [Hilton-Jones, 2014]. The 
diagnostic review will usually include a repeat 
diagnostic muscle biopsy, as with the passage of 
time, degenerative features of non-PM/DM dis-
eases can accumulate and become more conspic-
uous [Brady et al. 2014].
Treating skeletal muscle disease
Given that the IIM pathological process involves 
autoimmune inflammation, it is no surprise that 
current treatment approaches focus on the use of 
immunosuppression. Corticosteroids remain the 
mainstay of initial treatment, despite the absence 
of good-quality evidence to support their use. 
Where there is clinical urgency, intravenous 
methylprednisolone can be used instead. A ster-
oid-sparing agent is then usually commenced 
(e.g. azathioprine, methotrexate or mycopheno-
late). There is little to guide drug choice in this 
aspect, although mechanism of action may be 
considered and treatment tailored according to 
prominent aspects of disease. Intravenous immu-
noglobulins (IVIg) are also commonly used, par-
ticularly in accurately diagnosed but truly 
steroid-resistant cases.
This review does not discuss all potential treat-
ment options, but instead highlights some more 
novel considerations. A broader review of the 
pharmacological options for treating IIM can be 
found in the Cochrane review by Gordon and col-
leagues [Gordon et al. 2012], and in a more recent 
systematic review by Vermaak and colleagues 
[Vermaak et al. 2015]. It is important to remem-
ber that noninflammatory mechanisms also con-
tribute to muscle damage. There is, therefore, a 
potential role for intervention targeting these 
pathways, which will briefly be discussed.
Tacrolimus. The safety and efficacy of tacrolimus 
is well documented. There are sound biological 
reasons to consider the use of tacrolimus in IIM, 
although the evidence base supporting its efficacy 
is small and of low quality. There has recently 
been one prospective, open-label study and two 
retrospective controlled studies investigating its 
use in IIIM.
In the prospective open label study, tacrolimus 
was used in nine patients with refractory IIM 
[Matsubara et  al. 2012]. Eight of these patients 
were found to show clinical improvements after 6 
months with minimal adverse effects. A retrospec-
tive controlled study of 49 previously untreated 
patients with IIM complicated by interstitial lung 
disease, involved 25 patients receiving tacrolimus 
and 24 receiving conventional therapies [Kurita 
et  al. 2015]. After adjustment, the tacrolimus 
group had significantly longer event-free (death or 
other adverse event) survival as compared with the 
conventional therapy group [weighted hazard 
ratio (HR) 0.32, 95% confidence interval (CI) 
0.14–0.75, p = 0.008]. In addition, the tacrolimus 
group had significantly longer disease-free survival 
as compared with the conventional therapy group 
(weighted HR 0.25, 95% CI 0.10–0.66, p = 
0.005). A further retrospective controlled study 
examined 23 patients with IIM treated with 
prednisolone plus tacrolimus compared with 19 
Therapeutic Advances in Musculoskeletal Disease 8(4)
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treated with prednisolone plus conventional ther-
apy [Yokoyama et  al. 2015]. A steroid-sparing 
effect of tacrolimus over conventional therapy 
was identified, which persisted over the 36 
months of the study; at completion the median 
prednisolone dose was 4.75 mg in the tacrolimus 
group versus 10 mg in the conventional-therapy 
group, p = 0.02.
Rituximab. A large (n = 200, although 48 
had juvenile DM) randomized controlled trial 
examining the efficacy of rituximab adminis-
tered early versus late in the treatment of refrac-
tory IIM has recently been completed [Oddis 
et al. 2005]. There was no difference in the time 
to reach the IMACS definition of improvement 
between the two groups (the primary outcome). 
However, most patients (83%) did improve. It is 
argued that the result reflects a lack of statisti-
cal power to distinguish between the benefits of 
early versus late treatment, rather than a failure 
of rituximab per se.
Tociluzimab. Tocilizumab is an interleukin-6 
(IL-6) receptor blocker and as such, has poten-
tial use in the treatment of IIM. IL-6 has been 
found at increased levels in IIM muscles [Lepidi 
et  al. 1998] and serum IL-6 levels have been 
shown to correlate with the Myositis Intention-
to-Treat Activity Index (MITAX) disease activity 
score [Gono et al. 2014]. The use of tocilizumab 
has previously been described in two patients 
with PM [Narazaki et al. 2011] and one with DM 
[Kondo et al. 2014] with a suggestion of prom-
ise. A randomized controlled trial of tocilizumab 
in refractory IIM is ongoing [ClinicalTrials.gov 
identifier: NCT02043548].
Other ongoing clinical trials. There are a num-
ber of ongoing phase II and phase III clinical tri-
als of novel therapies for IIM:
1. Belimumab [ClinicalTrials.gov identifier: 
NCT02347891] is an inhibitor of B-cell 
activating factor (BAFF) which is currently 
used in the treatment of systemic lupus ery-
thematosus and is the subject of a phase II/
III trial in PM and DM.
2. BAF312 [ClinicalTrials.gov identifier: 
NCT01801917] is a sphingosine 1-phos-
phate (S1P) receptor modulator, which 
inhibits lymphocyte egress from lymph 
nodes and is currently the subject of a phase 
II trial in patients with PM.
3. A phase II trial of IMO-8400 [ClinicalTrials.
gov identifier: NCT02612857], an antago-
nist of Toll-like receptors (TLRs) 7, 8 and 
9 is ongoing in patients with DM.
4. Gevokizumab [EudraCT number: 2012-
005772-34], which binds to interleukin-
1-beta, is the subject to a phase II trial in 
patients with PM, DM or NAM.
Interestingly, the inclusion criteria in some ongo-
ing clinical trials in IIM still refer to the Bohan 
and Peter diagnostic criteria.
Creatine supplementation. Reduced skeletal 
muscle total creatine and increased urinary cre-
atine excretion (suggesting muscle catabolism) 
are observed in patients with neuromuscular 
disorders, including IIM [Chung et al. 2007]. A 
recent study (n = 37) has demonstrated improved 
functional performance in PM and DM patients 
receiving dietary supplementation with creatine 
in combination with a home exercise programme, 
compared with those receiving placebo and exer-
cise over 6 months [Chung et al. 2007]. The use 
of creatine supplementation in IIM has been 
reviewed by Cochrane, with the authors conclud-
ing that there is evidence supporting the sugges-
tion that creatine supplementation can improve 
functional outcomes in IIM [Kley et al. 2013].
Exercise. The role of exercise as a potential 
therapeutic modality in IIM has recently been 
reviewed [Lightfoot and Cooper, 2016]. In the 
past, there was concern that exercise may be dan-
gerous in those with IIM, perhaps generated as 
a result of the observation that CK can rise after 
exercise. However, reassurance is provided by 
results from a number of studies examining aero-
bic and resistive exercise programmes in patients 
with IIM. In patients with PM and DM, increased 
muscle strength, improved disease-activity scores 
and gene expression profiles showing a reduc-
tion in proinflammatory and profibrotic gene 
networks has been observed in response to a 
supervised 7-week resistance exercise programme 
[Alexanderson et al. 2007; Nader et al. 2010]. It is 
suggested that exercise may therefore exert a dis-
ease-modifying effect at a molecular level through 
modification of gene expression. In further sup-
port of this hypothesis, Munters and colleagues 
recently reported downregulation of genes related 
to inflammation and endoplasmic reticulum (ER) 
stress in a group of seven patients with DM or PM 
that underwent a 12-week endurance exercise 
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programme compared with a nonexercised con-
trol group [Munters et al. 2016].
Endoplasmic reticulum stress and reactive-oxygen 
species. To the frustration of many of those treat-
ing IIM patients, outcomes with immunosuppres-
sive therapy remain unsatisfactory. Even with 
aggressive immunosuppression, significant and 
irreversible disease damage often remains. The 
reasons for this are poorly understood, but mech-
anisms are thought to involve noninflammatory 
cell-mediated pathways. Recent work has focused 
on the role ER stress and subsequent downstream 
effects potentially detrimental to muscle function, 
including the generation of toxic reactive-oxygen 
species and mitochondrial dysfunction [Lightfoot 
et al. 2015]. Further work on elucidating the exact 
mechanisms at play will be important in the iden-
tification of new therapeutic targets in IIM.
Myositis is a multisystem disorder
In treating a patient with IIM, one must look 
beyond the skeletal muscle. Disease of the skin, 
heart, lungs and the association with malignancy 
are key issues that need addressing. In many cases, 
screening for subclinical disease must be instituted 
to ensure expeditious detection of potential compli-
cations so that appropriate intervention might take 
place. Importantly, these extramuscular manifesta-
tions can be predicted by a patient’s serological 
profile. A full review of treating the extra-muscular 
aspects of IIM will not follow, but we will mention 
a few key aspects to consider.
Cardiac disease. Myocardial disease in IIM is 
under-recognized and is associated with high lev-
els of morbidity and mortality [Lundberg, 2006]. 
Most cardiac disease is subclinical, and feasible 
methods of screening are limited in many clini-
cal settings (e.g. poor access to cardiac MRI). The 
use of a panel of biochemical assays accounting 
for markers released differentially from skeletal 
and cardiac muscle may offer accurate screening 
for cardiac involvement in IIM in the clinical set-
ting [Hughes et al. 2015]. Importantly, it is now 
recognized that troponin-T can be released from 
regenerating skeletal muscle and as such, is not 
a reliable marker of cardiac involvement in IIM 
[Bodor et al. 1997].
Malignancy. Whilst the association of adult 
DM with malignancy is well established, it is now 
possible to refine the assessment of malignancy 
risk using serology. In particular, the presence of 
anti-TIF1-gamma antibodies is highly associated 
with malignancy and intense initial and regu-
larly repeated screening is likely warranted in this 
group.
Malignancy screening is often performed at the 
discretion of the treating physician and there are 
no firm recommendations dictating which inves-
tigations should be performed (e.g. endoscopy, 
abdominal ultrasound, PET/CT) and the interval 
between them. In the Lambert-Eaton myasthenic 
syndrome, prediction scores have been produced 
which allow a tailored approach for screening for 
small cell lung cancer [Titulaer et al. 2011]. There 
is currently no similar work in DM, although it 
would be assumed that serological testing for 
TIF1-gamma antibodies would form part of the 
scoring system.
A practical approach to managing myositis
Whilst bearing in mind the heterogeneity of IIM 
and the limited evidence base, a number of prac-
tical recommendations can be made about the 
general management. It is our view that patients 
with IIM should be referred to a specialist clinic 
for ongoing care. The experienced teams of 
healthcare professions in such clinics can mini-
mize the risk of diagnostic error and also have 
access to clinical trials of potential new IIM thera-
pies. Access to physiotherapy and other allied 
health professionals is also of key importance. 
The use of long courses of high-dose corticoster-
oids requires care regarding the potential for 
complications, including effects on bone health.
Depending upon the severity of presentation, par-
ticularly in terms of the degree of muscle weak-
ness, corticosteroids should be commenced either 
orally (e.g. prednisolone 1 mg/kg up to 100 mg) 
or intravenously (e.g. methylprednisolone, 1 g/day 
for 3 days, then converting to oral prednisolone). 
IVIgs are also occasionally used in this setting, 
although practice differs between specialists. 
Around 4 weeks of high-dose corticosteroid treat-
ment may be required to induce disease suppres-
sion. This should include improvements in a 
variety of disease-activity clinical-outcome meas-
ures including muscle strength, and not just a 
fall in the CK level. At this time (or before, if 
preferred), a steroid-sparing agent is usually 
commenced and the corticosteroid dose is grad-
ually tapered. Commonly prescribed options 
include azathioprine, methotrexate, mycopheno-
late, cyclosporin and tacrolimus. A failure of 
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treatment response necessitates review of the 
diagnosis and consideration of other therapies, 
including rituximab or cyclophosphamide, the 
latter being of particular use in those with coexist-
ing interstitial lung disease.
Conclusions
1. Clinical assessment, together with muscle 
biopsy findings and autoantibody status, 
are key factors to consider when making a 
diagnosis of IIM, and in stratification of the 
‘IIM spectrum’ into disease subgroups.
2. Treatment stratified according to serotype 
(and in the future, likely also genotype) is 
increasingly being used to take account of 
the heterogeneity within the IIM spec-
trum. Subgroup classification is also 
important in terms of monitoring for com-
plications, such as malignancy and inter-
stitial lung disease.
3. Disease monitoring should include the use of 
standardized tools such as the IMACS’ dis-
ease-activity outcome measures. Other tools 
such as muscle MRI can be useful in identi-
fying areas of active muscle inflammation.
4. Treatment outcomes in IIM remain unsat-
isfactory. The evidence base to guide treat-
ment decisions is remarkably limited.
5. In addition to muscle inflammation, a num-
ber of noninflammatory cell-mediated 
mechanisms may contribute to weakness 
and disability, and for which no specific 
treatments are currently available.
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